Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1964 1
1969 2
1970 1
1971 1
1973 3
1974 2
1981 1
1982 2
1984 5
1985 2
1987 3
1988 2
1989 1
1990 2
1991 8
1992 6
1993 8
1994 8
1995 6
1996 10
1997 5
1998 10
1999 11
2000 5
2001 12
2002 9
2003 16
2004 19
2005 18
2006 24
2007 17
2008 16
2009 20
2010 26
2011 19
2012 22
2013 20
2014 12
2015 24
2016 15
2017 23
2018 28
2019 26
2020 27
2021 33
2022 25
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Results by year

Filters applied: . Clear all
Page 1
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: miyahara y. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: miyahara y. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, Emori M, Kato K, Endo M, Matsumoto Y, Kakunaga S, Sato E, Miyahara Y, Morino K, Tanaka S, Takahashi S, Matsuo F, Matsumine A, Kageyama S, Ueda T. Kawai A, et al. Among authors: miyahara y. Clin Cancer Res. 2023 Dec 15;29(24):5069-5078. doi: 10.1158/1078-0432.CCR-23-1456. Clin Cancer Res. 2023. PMID: 37792433 Free PMC article. Clinical Trial.
Percutaneous pulmonary artery debanding.
Tomita H, Fujii T, Kise H, Oyama N, Shimizu T, Nagaoka K, Tarui S, Miyahara Y, Ishino K. Tomita H, et al. Among authors: miyahara y. J Cardiol. 2021 Mar;77(3):307-312. doi: 10.1016/j.jjcc.2020.10.021. Epub 2020 Dec 2. J Cardiol. 2021. PMID: 33279375 Free article.
Beta(+)-thalassemia with hemochromatosis.
Uchihara M, Nouchi T, Harano T, Yamane M, Sakai H, Takabe K, Mae S, Maekawa S, Fukuma T, Miyahara Y, et al. Uchihara M, et al. Among authors: miyahara y. Intern Med. 1992 Aug;31(8):1060-4. doi: 10.2169/internalmedicine.31.1060. Intern Med. 1992. PMID: 1362099 Free article.
Toll-like receptor 9-positive plasmacytoid dendritic cells promote Th17 immune responses in oral lichen planus stimulated by epithelium-derived cathepsin K.
Miyahara Y, Chen H, Moriyama M, Mochizuki K, Kaneko N, Haque ASMR, Chinju A, Kai K, Sakamoto M, Kakizoe-Ishiguro N, Yamauchi M, Ogata K, Kiyoshima T, Kawano S, Nakamura S. Miyahara Y, et al. Sci Rep. 2023 Nov 7;13(1):19320. doi: 10.1038/s41598-023-46090-3. Sci Rep. 2023. PMID: 37935734 Free PMC article.
546 results